Safety and Tolerability of Ultra-Rush Induction, Less than One Hour, of Sublingual Immunotherapy in Children

Background: The safety and tolerability of sublingual immunotherapy (SLIT) has been documented in allergic patients both in the build-up phase as well as during maintenance, but only two studies have evaluated the occurrence of adverse reactions with an ultra-rush regimen of SLIT induction in a mixe...

Full description

Saved in:
Bibliographic Details
Published in:International Archives of Allergy and Immunology 2006-01, Vol.139 (2), p.149-152
Main Authors: Tripodi, S., Di Rienzo Businco, A., Benincori, N., Scala, G., Pingitore, G.
Format: Article
Language:English
Subjects:
Administration, Sublingual
Adolescent
Allergens - administration & dosage
Allergens - adverse effects
Allergies
Asthma - therapy
Biological and medical sciences
Child
Child, Preschool
Children & youth
Conjunctivitis, Allergic - therapy
Dermatitis, Atopic - therapy
Desensitization, Immunologic - adverse effects
Desensitization, Immunologic - methods
Female
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
Hypersensitivity, Immediate - drug therapy
Immune system
Immunopathology
Male
Medical sciences
Rhinitis, Allergic, Perennial - therapy
Safety
Short Communication
Side effects
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The safety and tolerability of sublingual immunotherapy (SLIT) has been documented in allergic patients both in the build-up phase as well as during maintenance, but only two studies have evaluated the occurrence of adverse reactions with an ultra-rush regimen of SLIT induction in a mixed paediatric/adult population. Moreover one of these two studies used a chemically modified extract (allergoid). The aim of the present study was to evaluate the occurrence of immediate or late adverse reactions in allergic children after a very fast (40 min) ultra-rush SLIT induction with two different allergen extract solutions. Methods: We studied 100 children (64 boys, mean age of 9.6 years, range 3.5–16.8), with a history of intermittent/persistent rhinitis and/or intermittent/mild persistent asthma due to inhalant allergens. The ultra-rush build-up phase involved the administration, every 10 min, of increasing doses of the highest-concentration vial of SLIT of two different manufacturers (Anallergo and Stallergènes). Results: All patients completed the treatment, side-effects have been recorded in 19% of the cases: 10% within 1 h after the build-up phase, 7% within 48 h and 2% mixed. A major difference (p = 0.0001) was recorded between Anallergo (6 patients, 8.7%) and Staloral (13 patients, 41.9%), but all the reactions were mild: principally oral symptoms, in 1 case rhinorrhoea and cough, and delayed abdominal pain and diarrhoea in another patient. Conclusions: No severe adverse reactions were observed with this ultra-rush SLIT induction also in the paediatric age; statistical differences have been documented between the two different extracts.
ISSN:1018-2438
1423-0097
1365-2567
DOI:10.1159/000090391